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Abstract: BACKGROUND Enthesitis is a hallmark of spondyloarthritis (SpA) with a substantial impact
on quality of life. Reports of treatment effectiveness across individual enthesitis sites in real-world patients
with axial SpA (axSpA) are limited. We investigated the evolution of enthesitis following tumor necrosis
factor inhibitor (TNFi) initiation in axSpA patients, both cumulatively and at specific axial and peripheral
sites. METHODS AxSpA patients in the Swiss Clinical Quality Management Registry were included if
they initiated a TNFi, had an available Maastricht Ankylosing Spondylitis Enthesitis Score, modified
to include the plantar fascia (mMASES, 0-15), at start of treatment and after 6 and/or 12 months
and ฀12 months follow-up. Logistic regression models were utilized to analyze explanatory variables for
enthesitis resolution. RESULTS Overall, 1668 TNFi treatment courses (TCs) were included, of which
1117 (67%) had active enthesitis at baseline. Reduction in mMASES at the 6- and 12-month timepoints
was experienced in 72% and 70% of TCs, respectively. Enthesitis resolution at 6/12 months occurred in
37.9%/43.0% of all TNFi TCs and 40.7%/50.9% of first TNFi TCs. At 6 months, a significant reduction
in the frequency of enthesitis was observed at all sites, except for the Achilles tendon and plantar fascia
among first TNFi TCs, while at 12 months, reduction was significant at all sites in both TC groups.
Enthesitis resolved in 60.3-77% across anatomical sites, while new incident enthesitis occurred in 4.0-
13.5% of all TNFi TCs at 12 months. Both baseline and new-incident enthesitis occurred most frequently
at the posterior superior iliac spine and the fifth lumbar spinous process. Younger age and lower mMASES
at baseline were predictors of complete enthesitis resolution, while female sex and second- or later-line
TNFi treatment were associated with persistence of enthesitis at 12 months. CONCLUSION In real-world
axSpA patients treated with a TNFi, enthesitis improved in the majority of patients across all anatomical
sites. Significant improvement at the Achilles and plantar fascia entheses was observed only at 12 months.
Complete and site-specific enthesitis resolution occurred in ฀40% and ฀60% of TCs evaluated at 12 months,
with a low incidence of new site-specific enthesitis. TRIAL REGISTRATION Not applicable.
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Abstract
Background: Enthesitis is a hallmark of spondyloarthritis (SpA) with a substantial impact on quality of life. Reports
of treatment effectiveness across individual enthesitis sites in real-world patients with axial SpA (axSpA) are limited.
We investigated the evolution of enthesitis following tumor necrosis factor inhibitor (TNFi) initiation in axSpA
patients, both cumulatively and at specific axial and peripheral sites.
Methods: AxSpA patients in the Swiss Clinical Quality Management Registry were included if they initiated a TNFi,
had an available Maastricht Ankylosing Spondylitis Enthesitis Score, modified to include the plantar fascia (mMASES,
0–15), at start of treatment and after 6 and/or 12 months and ≥12 months follow-up. Logistic regression models
were utilized to analyze explanatory variables for enthesitis resolution.
Results: Overall, 1668 TNFi treatment courses (TCs) were included, of which 1117 (67%) had active enthesitis at
baseline. Reduction in mMASES at the 6- and 12-month timepoints was experienced in 72% and 70% of TCs,
respectively. Enthesitis resolution at 6/12 months occurred in 37.9%/43.0% of all TNFi TCs and 40.7%/50.9% of first
TNFi TCs. At 6 months, a significant reduction in the frequency of enthesitis was observed at all sites, except for the
Achilles tendon and plantar fascia among first TNFi TCs, while at 12 months, reduction was significant at all sites in
both TC groups. Enthesitis resolved in 60.3–77% across anatomical sites, while new incident enthesitis occurred in
4.0–13.5% of all TNFi TCs at 12 months. Both baseline and new-incident enthesitis occurred most frequently at the
posterior superior iliac spine and the fifth lumbar spinous process. Younger age and lower mMASES at baseline
were predictors of complete enthesitis resolution, while female sex and second- or later-line TNFi treatment were
associated with persistence of enthesitis at 12 months.
Conclusion: In real-world axSpA patients treated with a TNFi, enthesitis improved in the majority of patients across
all anatomical sites. Significant improvement at the Achilles and plantar fascia entheses was observed only at 12
months. Complete and site-specific enthesitis resolution occurred in ≥40% and ≥60% of TCs evaluated at 12
months, with a low incidence of new site-specific enthesitis.
Trial registration: Not applicable.
Keywords: Axial spondyloarthritis, Enthesitis, Resolution, Tumor necrosis factor inhibitors
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Michael.J.Nissen@hcuge.ch
1Department of Rheumatology, Geneva University Hospital, 26 Avenue
Beau-Séjour, 1211, Geneva 14, Switzerland
Full list of author information is available at the end of the article
Nissen et al. Arthritis Research & Therapy          (2021) 23:165 
https://doi.org/10.1186/s13075-021-02534-7
Key points
1. Enthesitis is present in approximately two-thirds of
axial SpA patients in a real-world cohort at the time
of initiation of a TNF inhibitor
2. After 12 months of therapy with a first TNFi, more
than 50% of patients experienced complete
resolution of enthesitis.
3. While enthesitis improved across all anatomical
sites, resolution occurred more slowly at the
Achilles tendon and the plantar fascia.
Introduction
Axial spondyloarthritis (axSpA) is an inflammatory
rheumatic disease with a diverse clinical presentation
[1, 2]. AxSpA is characterized by excess bone formation that
results in bone fusion and sclerosis of the sacroiliac joints
and spine [1–4]. Chronic inflammatory back pain is the
most common symptom of axSpA, and the associated pain,
stiffness, and fatigue limit physical functioning and the abil-
ity to perform activities of daily living [2, 5]. Other musculo-
skeletal manifestations of axSpA include arthritis, dactylitis,
and enthesitis [1, 2]. Extra-articular manifestations, such as
acute anterior uveitis, psoriasis, and inflammatory bowel dis-
ease are also characteristic of axSpA [1, 2]. Consequently,
axSpA carries a significant patient burden and has a sub-
stantial impact on patients’ quality of life [1, 2, 5–8].
Enthesitis, defined as an inflammation of the tendon,
ligament, and/or joint capsule insertions into bone, is re-
ported in the majority of patients with spondyloarthritis
(SpA) [9] and is recognized as the distinctive patho-
logical process in SpA [10, 11]. Advanced imaging and
studies in animal models and humans have shown that
enthesitis is associated with diffuse effects on adjacent
connective tissue and underlying bone structures [11,
12]. Pathophysiological mechanisms of enthesitis in SpA
may include both mechanical and autoimmune features
[13, 14]. Repeated biomechanical stress is thought to
cause microdamage at the entheses, which in turn in-
duces an inflammatory response in the adjacent synovial
tissue leading to synovitis [11, 13, 14]. Enthesitis is
associated with higher disease activity, more disability,
work absenteeism, and a poorer quality of life in
axSpA patients [9].
Conventional synthetic disease-modifying anti-rheumatic
drugs (csDMARDs) have been used with some success to
treat peripheral arthritis in SpA patients; however, they
have not clearly demonstrated efficacy for the treatment of
enthesitis or the axial manifestations of axSpA [15–17]. In
contrast, tumor necrosis factor inhibitors (TNFi’s) have
been shown to be effective in improving or resolving enthe-
sitis in clinical trials in patients with axSpA [18–23]. How-
ever, other clinical trials evaluating the benefit of TNFi’s on
enthesitis in axSpA did not demonstrate a significant
improvement or reported results that varied by the assess-
ment utilized [24, 25]. It is important to note that many of
these studies tended to involve a rather small number of
patients, with a low baseline prevalence of enthesitis and
with enthesitis as a secondary outcome. Real-world data on
the effectiveness of TNFi’s for enthesitis in axSpA patients
is even more limited. Moreover, data on enthesitis site-
specific treatment effectiveness is rare, but required because
the effectiveness of TNFi’s on enthesitis may vary by enthe-
sitis site and therefore vary depending on the enthesitis
index utilized [25]. The objective of this analysis was to in-
vestigate the real-world treatment effectiveness of TNFi
therapy on enthesitis, both cumulatively and at specific
enthesitis locations, including the spine, thoracic cage,
Achilles tendon, and the plantar fascia, in patients with
axSpA initiating a TNFi.
Methods
Study design and data source
This observational cohort study utilized prospectively
collected data from the nationwide Swiss Clinical Quality
Management in Rheumatic Diseases (SCQM) registry in
inflammatory rheumatic diseases. This ongoing cohort of
patients with ankylosing spondylitis/axSpA was estab-
lished in 2005 [26] and provides an integrated feedback
system for rheumatologists and their patients to monitor
disease activity, disability, and radiographic damage using
standardized assessments [27, 28]. At registry inclusion,
demographic and disease characteristics, concomitant
treatments, laboratory values, and comorbidities were
collected by the treating rheumatologists [26]. Patients
completed self-administered questionnaires to assess their
disease state and quality of life [26]. Informed written con-
sent was obtained from all patients prior to inclusion in
the SCQM registry, and a regional ethics committee
(CER-VD, 2019-00278) provided approval for collection of
patient data from the SCQM cohort [26].
Participants
Included patients were ≥16 years of age with a diagnosis
of axSpA, as determined by a consultant rheumatologist,
and had initiated a TNFi after inclusion into the SCQM
registry. Patients were required to have available enthesi-
tis assessments (i.e., modified MASES [mMASES]; modi-
fied to include the plantar fascia) at TNFi initiation
(“baseline visit”; visits with a mMASES within 90 days
prior to TNFi treatment initiation start date were con-
sidered valid), ≥1 enthesitis assessment available during
the follow-up period, and a treatment course (TC) with
≥1 year of follow-up after treatment initiation. It was
therefore possible for a single patient to contribute sev-
eral TCs to the analysis. TCs with a particular TNFi
(e.g., with a change of dose or a brief pause in treatment)
in the same patient were merged if they corresponded to
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the same TNFi and if the end of the last dose of the last
TC was within a 90-day time window of the first dose of
the next TC. The follow-up period for a TC was defined
as the time interval between treatment initiation day
until the latest of the following days: last recorded visit,
last recorded treatment stop date, or last recorded treat-
ment adjustment date.
Outcomes
The mMASES included the 13 sites of the MASES: 1st
costochondral joints, 7th costochondral joints, iliac
crests, anterior superior iliac spines, posterior superior
iliac spines, insertion of Achilles tendons, and the 5th
lumbar spinous process, as well as 2 additional sites,
with inclusion of the plantar fascia insertion bilaterally,
for a total of 15 sites (range, 0–15) [29]. Among patients
presenting with enthesitis at baseline (mMASES≥1), both
enthesitis resolution (mMASES=0) and mMASES score
reduction at 6- and 12-month follow-ups were assessed
both overall and in the subset of TCs who were TNFi
naïve at baseline (i.e., first TNFi TC). Enthesitis
localization frequencies at the 15 mMASES sites were
examined at 6-month and at 12-month follow-ups.
Statistical analyses
Baseline demographic and clinical characteristics were
analyzed using descriptive statistics; continuous variables
were summarized as medians with IQR, and categorical
variables as frequencies and percentages of patients.
Regarding mapping of patient information to baseline, 6-
month and 12-month follow-up timepoints, we consid-
ered visits within the following intervals: baseline (0 to
−90 days), 6 months (±90 days), and 12 months (±90
days) respectively. For enthesitis localization change, an
intention to treat (ITT) approach was used whereby TCs
were analyzed regardless of whether the patient was still
under the same treatment at 6 and/or 12 months. Add-
itionally, we performed a sensitivity analysis following a
per protocol (PP) approach whereby we only considered
the subset of TCs where the patient remained on the ini-
tial treatment at 12 months. McNemar’s test or a Mid-p
method (if counts in the contingency tables were <25)
was used to compare the proportion of patients with
enthesitis at each mMASES site between baseline and 6
or 12 months, and the resultant P values were corrected
for multiplicity using the Holm-Bonferroni method
(correction was performed per set of comparisons for
the 2 follow-up timepoints and P<0.05 level of signifi-
cance was utilized).
Multiple missing value imputation by chained equa-
tions (MICE) was performed for baseline covariates
for all TNFi TCs. The missingness for these variables
varied from 1–15% for disease duration, height,
weight, HLA-B27, and ASAS classification, to 20–
30% for exercise score and ASDAS-CRP. In addition
to the most important variables presented in Table 1,
mMASES at follow-up timepoint was also included
in the imputation model. No evidence was found that
any of the baseline variables influenced the missing-
ness distribution and a missing-at-random (MAR)
data pattern was assumed. The MICE algorithm was
run with 75 imputations and 30 iterations. Diagnostic
measures were used to evaluate the convergence of
the MICE algorithm and distribution of imputed
values. We utilized logistic regression in order to
analyze the binary outcome of enthesitis resolution
and odds ratios were derived. The analyses were per-
formed with both MICE imputed data and complete
case data.
Results
Of 3325 identified TCs in 2130 patients with axSpA who
initiated TNFi therapy, 1668 TCs in 1393 patients
met all 3 entry criteria of a mMASES available at base-
line, at least another mMASES reported during follow-
up, and available follow-up of at least 12 months (Fig. 1).
The mean number (SD) of visits from baseline (0 to −90
days) to 12 months (± 90 days) in the group with non-
missing mMASES data was 2.7 (1.8). Regarding the TCs,
at baseline, the majority included men (53.1%), median
age was 42 years (IQR, 33–51), median disease duration
was 9 years (IQR, 4–18), and median Ankylosing Spon-
dylitis Disease Activity Score (ASDAS-CRP) was 3.3
(IQR, 2.6–3.9) (Table 1). The median mMASES was 2
(IQR, 0–4) and 67% of TCs (1117 of 1668) were enthesi-
tis positive (mMASES ≥1) at baseline; 23.5% were
simultaneously co-treated with a csDMARD, and most
TCs included patients receiving first-line TNFi therapy
(62.7%). At baseline, TNFi’s initiated included adalimu-
mab (30.2%), golimumab (23.7%), etanercept (23.6%),
infliximab (18.0%), and certolizumab (4.4%). Baseline
characteristics (Table 1) demonstrated that in the
subgroup with enthesitis at baseline there was a lower
proportion of men, lower rates of HLA-B27 positivity,
and higher BASDAI values, whereas age, BMI, disease
duration, and ASAS axial SpA criteria positivity were
similar between those with and without baseline
enthesitis.
Regarding TNFi TCs for patients with active enthe-
sitis at baseline (n=1117) and available enthesitis
assessments at 6 months (n=404) or 12 months (n=
698), a reduction in mMASES was experienced by
72% and 70%, respectively. Score distributions at
baseline and at the 6- and 12-month timepoints are
presented in Fig. 2A and B. Similar findings were ob-
served in the first TNFi TC subgroup (data not
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shown). Mean mMASES (SD) decreased from 2.9
(3.2) at baseline to 1.9 (2.8) at 6 months and to 1.8
(2.8) at 12 months in the all TC group and from 2.8
(3.0) at baseline to 1.6 (2.5) at 6 months and to 1.5
(2.7) at 12 months in the first TNFi subgroup.
Complete resolution of enthesitis (mMASES=0)
was observed in 153/404 patients (37.9%) at 6
months and 300/698 patients (43.0%) at 12 months
in the group including all TCs, compared with 98/
241 (40.7%) and 234/460 (50.9%), respectively, in the
first TNFi subgroup. Estimates from the PP analyses
were almost identical in direction, effect size, and
significance to the ITT approach.
At baseline, enthesitis was most frequently observed
at the fifth lumbar spinous process and the posterior
superior iliac spine and least frequently at the plantar
fascia (Fig. 3). In patients with active enthesitis at
baseline, there was a significant reduction from base-
line to 6-month follow-up in the frequency of enthe-
sitis at all observed sites, except for the left Achilles
tendon when including all TNFi TCs (Fig. 3A), and
across all sites, except for the right and left Achilles
tendons and the right plantar fascia in the first TNFi
subgroup (Fig. 3B). At 12-month follow-up, there was
a significant reduction from baseline in the frequency
of enthesitis at all observed sites in both the all TC
Table 1 Baseline characteristics of treatment courses for axSpA patients initiating a TNFi
Variable All TC
(n=1668 TCs)
All TC with mMASES ≥1
at baseline (n=1117)
All TC with mMASES = 0
at baseline (n=551)
Age (years), median (IQR) 42 (33–51) 43 (34–51) 41 (32-51)
Men, n (%) 886 (53.1) 531 (47.5) 355 (64.4)
























Enthesitis (mMASES >0) at baseline, n (%) 1117 (67.0) 1117 (100) -
mMASES, median (IQR) 2 (0–4) 3 (2–6) -
























Ever experienced arthritis, n (%) 963 (57.7) 707 (63.3) 256 (46.5)












csDMARD cotherapy, n (%) 392 (23.5) 274 (24.5) 118 (21.4)
TNFi line of therapy, n (%)
First line 1046 (62.7) 702 (62.9) 346 (62.8)
Second line 389 (23.3) 261 (23.4) 128 (23.2)
≥Third line 233 (14.0) 154 (13.8) 77 (14.0)
aPatients without ASAS axial SpA criteria positive were either ASAS axial SpA criteria negative or unknown due to missing variables
bASDAS disease activity states: inactive (<1.3), low (≥1.3 to <2.1), high (≥2.1 to ≤3.5), very high (>3.5)
cBASDAI scores range from 0 (no disease activity) to 10 (maximum disease activity)
ASAS Assessment of SpondyloArthritis international Society, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease
Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, HLA-B27 human leukocyte antigen B27, IQR
interquartile range, mMASES modified Maastricht Ankylosing Spondylitis Enthesitis Score (modified to include the plantar fascia), TCs treatment courses, TNFi
tumor necrosis factor inhibitor
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group (Fig. 3C) and the first TNFi subgroup (Fig. 3D).
Across enthesitis sites evaluated, enthesitis resolved in
60.3–77%, while new incident enthesitis occurred in
4.0–13.5% of all TNFi TCs at 12 months (Fig. 4). Incident
enthesitis, like baseline enthesitis, most frequently oc-
curred at the posterior superior iliac spine and the fifth
lumbar spinous process, whereas incident enthesitis least
frequently occurred at the plantar fascia, the anterior iliac
crest, and the Achilles tendon.
At the 12-month follow-up, younger age and lower
mMASES at baseline were predictors of complete
enthesitis resolution, while female sex and second- or
later-line TNFi treatment were associated with
persistence of enthesitis at 12 months in the MICE
pooled estimates (Fig. 5). Negative Assessment of
SpondyloArthritis international Society (ASAS) classi-
fication criteria status at baseline showed a trend
favoring enthesitis resolution in the MICE analysis
(P=0.06), which was not observed in the complete
case analysis (P=0.2). The MICE pooled 6-month esti-
mates were similar to the 12-month estimates, with
younger age, lower mMASES, and negative ASAS
classification criteria status at baseline being associ-
ated with the resolution of enthesitis, while female
sex was associated with the persistence of enthesitis.
Discussion
Although many clinical trials have supported the use
of TNFi’s for the treatment of enthesitis [22, 23, 30],
the effectiveness of TNFi’s for enthesitis in patients
with axSpA in a real-world setting is largely unknown.
In this analysis of real-world axSpA patients using
data from the SCQM registry, we demonstrate that the
mMASES decreased in 72% and 70% of patients at the
6- and 12-month timepoints, respectively. Complete
resolution of enthesitis (mMASES=0) occurred in
Fig. 1 Selection of axSpA Study Sample. Number of treatment courses for each category are shown. MASES, Maastricht ankylosing
spondylitis enthesitis score; SCQM, Swiss Clinical Quality Management; TNFi, tumor necrosis factor inhibitors
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37.9% and 43.0% of all TCs at 6 and 12 months, re-
spectively, and in 40.7% and 50.9% of first TNFi TCs
at 6 and 12 months, respectively. A possible explan-
ation for the difference in enthesitis resolution be-
tween 6 and 12 months could be that longer TNFi
treatment leads to a better response. Overall, in this
axSpA patient population, a significant decrease in the
frequency of enthesitis involvement was observed at
all mMASES sites after 12 months, suggesting the
real-world effectiveness of TNFi for the treatment of
enthesitis.
It is interesting to note the differences in the im-
provement of site-specific enthesitis from baseline to
6 months and baseline to 12 months, whereby a sig-
nificant improvement from baseline to 6 months was
observed at all sites, except the Achilles tendon and
the plantar fascia, which was particularly evident for
the subgroup with a first TNFi. In contrast, all enthe-
seal sites, including the Achilles tendon and the plan-
tar fascia, demonstrated significant improvement from
baseline to 12 months. This suggests that other fac-
tors, such as weight-bearing activities and higher
mechanical stress at the entheses around the ankle,
may lead to the requirement for a longer period of
TNF inhibition in order to see a significant clinical
improvement.
Data on incident enthesitis in SpA patients is very
limited and largely restricted to patients with psoriatic
arthritis. In patients with peripheral SpA included in
the ABILITY-2 trial, 3.6% of patients treated with
adalimumab presented new-onset enthesitis of the
Achilles tendon at 12 weeks [18], which is similar to
the rate of 5.3% in our population of axial SpA. Con-
versely, a significantly higher proportion of patients
(10.9%) in the placebo group presented new-onset
enthesitis at the Achilles tendon in ABILITY-2 [18].
New-onset enthesitis at the insertion of the plantar
fascia was observed in 4.8% of treated patients in the
ABILITY-2 trial (and in 8.7% of the placebo group)
[18], which once again is very similar to the rate of
4.1% in our population. The higher rates of incident
enthesitis observed at the 5th lumbar spine and the
posterior superior iliac spine may in part be a reflec-
tion of non-inflammatory processes, such as degenera-
tive disease of the lumbar spine.
The mean mMASES in our study population of 2.9 (SD,
3.2) was somewhat lower than that generally observed in
randomized trials, such as the RAPID-axSpA trial with
mean MASES scores of 4.7 in radiographic-axSpA pa-
tients and 5.6 in non-radiographic-axSpA patients [22].
Nevertheless, in our cohort, there were significant reduc-
tions of mean mMASES over 12 months to 1.8 in the all
TC group and to 1.5 in the first TNFi subgroup. The
RAPID-axSpA trial reported resolution rates of enthesitis
of 53.8–55.4% in radiographic-axSpA patients and of
47.1–49.3% in nonradiographic-axSpA patients at 24
weeks [22], which are similar to the rates of 38–51% in
our study. The RHAPSODY trial [23] reported resolution
of plantar fascia enthesitis in 70.5% of patients at week 12,
which is similar to the findings for our population at 12
months (resolution in 70.0–71.9% of TCs).
Patients with many positive enthesitis sites may be
more likely to present with concomitant fibromyalgia,
Fig. 2 mMASES at Baseline and (A) 6 or (B) 12 Months. Each line on
the plot connects the before and after mMASES values of a
treatment course. More than one treatment course may have
overlapping lines. The line colours indicate whether mMASES
reduced, increased, or stayed the same. The numbers at baseline
and the 6-month and 12-month time points indicate the number of
TCs with the corresponding score. The black line indicates
the evolution of the mean mMASES score between the 2 time
points. For the assessment of modified MASES at the 6-month time
point, values in interval [6 ± 3 months] were used and at the 12-
month time point, values in interval [12 ± 3 months] were used.
mMASES, modified Maastricht ankylosing spondylitis enthesitis
score (modified to include the plantar fascia); TC, treatment course;
TNFi, tumor necrosis factor inhibitor
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and the clinical overlap of these conditions may be
more frequent in women than in men with axSpA
[31, 32]. AxSpA patients with concomitant fibromyal-
gia could be expected to respond less efficiently to
TNFi. In the overall population of the current study,
47/1668 patients presented with a diagnosis of con-
current fibromyalgia, including 8 men (1.0%) and 39
women (5.0%). The rate of fibromyalgia in the sub-
group with a mMASES≥1 at baseline was 3.5%. These
proportions of fibromyalgia are somewhat lower than
estimates in the literature that range from 4 to 25%
in axSpA patients [33].
This current study has a number of strengths, most
importantly that it is the largest real-world study to
date evaluating the effectiveness of TNFi on enthesi-
tis in axSpA patients. While there are some data on
the evolution of enthesitis in routine clinical practice
following treatment with TNFi’s in both psoriatic
arthritis (PsA) and peripheral SpA, there are almost
no real-world data regarding axial SpA. The fact that
we utilized the MASES is also advantageous, as in
axial SpA, this score has demonstrated better correl-
ation with BASDAI and BASFI than the Leeds
Enthesitis Index [34]. In addition, we include data
from both 6- and 12-month timepoints, which is im-
portant as enthesitis may resolve more slowly than
other manifestations of axial SpA. In our manuscript,
we report information on both overall incident
enthesitis, as well as incident enthesitis by site, which
is rarely described.
One of the limitations of this analysis is that no
direct control group was available, and therefore, we
cannot make any definitive statements about the
causal effect of TNFi treatment on enthesitis reduc-
tion or resolution. Registry data are limited to the in-
formation collected at each visit, and patients may
not have follow-up visits at timepoints of interest,
making it more challenging to assess the effectiveness
of treatments. It is unlikely that the ASAS axial SpA
classification criteria-negative patients in our cohort
in fact presented PsA, as in Switzerland there is a
separate cohort for PsA and, additionally, cutaneous
psoriasis was present in only 4% of the study
population.
We hereby demonstrate that in a large real-world
population of patients with axial SpA treated with a
Fig. 3 Enthesitis Localization at Baseline and 6 (A, C) or 12 (B, D) Months. Patients had active enthesitis at baseline and received TNFi therapy.
Data are presented for all TCs and for the subgroup of first TNFi TCs. P value corrected for multiplicity (using the Holm-Bonferroni method). TC,
treatment course; TNFi, tumor necrosis factor inhibitor. *P<0.05, **P<0.01, and ***P<0.001
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Fig. 5 Explanatory Variables of Enthesitis Resolution at 12-Month Follow-up (n=698). Logistic regression analysis for resolution of enthesitis based
on multiple imputation of missing baseline covariate data. Analysis was performed with 698 treatment courses in patients who initiated TNFi and
with available enthesitis assessments at 12-month follow-up. The numbers of enthesitis resolutions observed at 12-month follow-up was 300. All
variables presented represent values at baseline. BMI is a categorical variable with levels defined as underweight (BMI <18.5), normal (BMI 18.5–
24.9), and overweight (BMI >24.9). ASAS classification negative indicates patients not meeting ASAS criteria for axial spondyloarthritis. Predictors
with 95% CIs that extend beyond the x-axis scale upper limit of 2 are indicated with an arrowhead at the end of the error bar. ASDAS-CRP,
Ankylosing Spondylitis Disease Activity Score–C-reactive protein; ASAS, Assessment of SpondyloArthritis international Society; BMI, body mass
index; mMASES, modified Maastricht ankylosing spondylitis enthesitisscore (modified to include the plantar fascia); TNFi, tumor necrosis
factor inhibitor
Fig. 4 Incident and Resolved Enthesitis by Location at 12 months. Enthesitis by location was assessed for all TNFi treatment courses with non-
missing follow-up data at 12 months (n=1038). BL, baseline; TNFi, tumor necrosis factor inhibitors
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TNFi, a reduction in enthesitis was experienced by
at least 70% of patients, while the complete reso-
lution of enthesitis at 12 months was experienced by
more than half of patients receiving a first TNFi.
Significant reduction of enthesitis was observed at all
sites at 6 months, except for the Achilles tendon
and the plantar fascia, and at all sites at 12 months,
suggesting that the ankle entheses may be more
prone to mechanical strain and therefore require
additional time for resolution. Finally, we describe
the predictors of complete enthesitis resolution,
which could be useful knowledge for the clinician
initiating a TNFi.
Importance and relevance of the study
We describe the real-world effectiveness of TNFi therapy
on enthesitis in patients with axial SpA, both cumulatively
and at specific enthesitis locations. The variability of the
therapeutic response based on the localization of the
enthesis and the factors predictive of resolution should be
useful knowledge for the clinician initiating a TNFi.
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